Evaluate the osteogenic effect of locally applied 1% metformin gel on bone volume formation after jaw cystic defects enucleation
o Healthy adults patients .
Confirmed radiolucent odontogenic cysts requiring enucleation.
The cystic defect range 5cmto ≤15cm (19)
Good oral hygiene and strict commitment to attend follow-up scans.
o Medically compromised patients
Heavy smokers (consuming more than 10 cigarettes a day).
Active, acute purulent infection at the surgical site (this must be resolved before surgery).
Parallel
For the Experimental Arm: 1% Metformin Gel
Drug1\. For 1% Metformin Gel (Experimental Arm): Intervention Description: Pure metformin hydrochloride powder is dissolved into a biocompatible, in-situ gelling base at a concentration of 10 mg/ml to prepare a high-viscosity 1% metformin gel. Following surgical enucleation and thorough irrigation of the odontogenic cystic cavity, the gel is applied directly into the residual bony defect to act as a bioactive tissue-engineering matrix.
For the Comparator / Control Arm: Placebo Gel
DrugFor Placebo Gel (Comparator Arm): Intervention Description: A visually and physically identical methylcellulose-based placebo gel. Following surgical enucleation and thorough irrigation of the odontogenic cystic cavity, the placebo gel is applied directly into the residual bony defect in an identical manner to maintain double-blinding
Absolute Volume
Absolute bone volume (mm3) measured using Cone Beam Computed Tomography (CBCT) coupled with 3D volumetric segmentation software (e.g., Mimics).
Relative Bone density
Measurement of relative bone density expressed as Gray Scale Value (GSV) using Cone Beam Computed Tomography (CBCT).
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
